Human embryo genome editing: an interdisciplinary approach
- Authors: Grebenshchikova E.G.1,2, Andreyuk D.S.3,4,5, Volchkov P.Y.6,7, Vorontsova M.V.3,7, Ginter E.K.8, Izhevskaya V.L.8, Lagunin A.A.1,9, Polyakov A.V.8, Popova O.V.10, Smirnikhina S.A.8, Tishchenko P.D.10, Trofimov D.Y.11, Kutsev S.I.8
-
Affiliations:
- Pirogov Russian National Research Medical University
- Institute of Scientific Information for Social Sciences of the Russian Academy of Sciences
- Russian Association for the Advancement of Science
- Lomonosov Moscow State University
- Psychiatric Clinical Hospital No. 1 n.a. N.A. Alekseev of Moscow Health Department
- Moscow Institute of Physics and Technology
- The National Medical Research Center for Endocrinology
- Research Centre for Medical Genetics
- Institute of Biomedical Chemistry, Moscow
- The Institute of Philosophy of the Russian Academy of Sciences
- National Medical Research Center for Obstetrics, Gynecology and Perinatology Named after Academician V.I. Kulakov
- Issue: Vol 76, No 1 (2021)
- Pages: 86-92
- Section: CELL TRANSPLANTOLOGY AND TISSUE ENGINEERING: CURRENT ISSUES
- URL: https://journals.rcsi.science/vramn/article/view/125720
- DOI: https://doi.org/10.15690/vramn1269
- ID: 125720
Cite item
Full Text
Abstract
The prospects for the human embryos genome editing cause intense debates both in the scientific community and in general public. While the main attention of scientists is focused on the safety, effectiveness and clinical feasibility of the inherited genome editing, the public pays attention to the bioethical aspects of the issue - the prospects of a “baby design”, the development of new forms of social inequality and intervention in human evolution. The authors conducted an interdisciplinary analysis of medical genetics and bioethical issues of human embryo genome editing, revealed the possibilities and limitations of genome editing technology, and considered the specifics of ethical discussions. The conceptualization of the main approaches of natural and social sciences in a general theoretical framework made it possible not only to take into account the complex nature of the issues, but also to create the prerequisites for its further productive discussion.
Full Text
##article.viewOnOriginalSite##About the authors
Elena G. Grebenshchikova
Pirogov Russian National Research Medical University; Institute of Scientific Information for Social Sciences of the Russian Academy of Sciences
Author for correspondence.
Email: aika45@yandex.ru
ORCID iD: 0000-0002-5007-7626
SPIN-code: 2713-4222
PhD
Russian Federation, Moscow; MoscowDenis S. Andreyuk
Russian Association for the Advancement of Science; Lomonosov Moscow State University; Psychiatric Clinical Hospital No. 1 n.a. N.A. Alekseev of Moscow Health Department
Email: denis.s.andreyuk@yandex.ru
ORCID iD: 0000-0002-3349-5391
SPIN-code: 8083-4058
PhD in Biology
Russian Federation, Moscow; Moscow; MoscowPavel Y. Volchkov
Moscow Institute of Physics and Technology; The National Medical Research Center for Endocrinology
Email: volchkov.office@gmail.com
ORCID iD: 0000-0001-9794-6297
SPIN-code: 9611-8768
PhD in Biology
Russian Federation, Dolgoprudny; MoscowMaria V. Vorontsova
Russian Association for the Advancement of Science; The National Medical Research Center for Endocrinology
Email: oprf-nayka@yandex.ru
ORCID iD: 0000-0002-9124-294X
SPIN-code: 4168-6851
MD, PhD
Russian Federation, Moscow; MoscowEvgeny K. Ginter
Research Centre for Medical Genetics
Email: ekginter@mail.ru
ORCID iD: 0000-0001-6920-6726
SPIN-code: 1738-3724
MD, PhD in Biology, Professor, Academician of the RAS
Russian Federation, MoscowVera L. Izhevskaya
Research Centre for Medical Genetics
Email: izhevskaya@med-gen.ru
ORCID iD: 0000-0002-7246-5144
SPIN-code: 3941-9294
MD, PhD
Russian Federation, MoscowAlexey A. Lagunin
Pirogov Russian National Research Medical University; Institute of Biomedical Chemistry, Moscow
Email: alexey.lagunin@ibmc.msk.ru
ORCID iD: 0000-0003-1757-8004
SPIN-code: 7902-2654
PhD in Biology, Professor of the RAS
Russian Federation, Moscow; MoscowAleksandr V. Polyakov
Research Centre for Medical Genetics
Email: polyakov@med-gen.ru
SPIN-code: 6453-3097
MD, PhD in Biology, Professor, Corresponding Member of the RAS
Russian Federation, MoscowOlga V. Popova
The Institute of Philosophy of the Russian Academy of Sciences
Email: j-9101980@yandex.ru
ORCID iD: 0000-0002-3825-7544
SPIN-code: 4085-4783
PhD
Russian Federation, MoscowSvetlana A. Smirnikhina
Research Centre for Medical Genetics
Email: smirnikhinas@gmail.com
ORCID iD: 0000-0002-1558-3048
SPIN-code: 6884-6170
MD, PhD
Russian Federation, MoscowPavel D. Tishchenko
The Institute of Philosophy of the Russian Academy of Sciences
Email: pavel.tishchenko@yandex.ru
ORCID iD: 0000-0001-7304-7027
SPIN-code: 6250-6089
MD, PhD, Professor
Russian Federation, MoscowDmitriy Y. Trofimov
National Medical Research Center for Obstetrics, Gynecology and Perinatology Named after Academician V.I. Kulakov
Email: d.trofimov@dna-technology.ru
SPIN-code: 3067-2804
PhD in Biology, Professor of the RAS
Russian Federation, MoscowSergey I. Kutsev
Research Centre for Medical Genetics
Email: mgnc@med-gen.ru
ORCID iD: 0000-0002-3133-8018
SPIN-code: 5544-8742
MD, PhD, Professor, Corresponding Member of the RAS
Russian Federation, MoscowReferences
- ClinicalTrials.gov [Internet]. [cited 19.09.2019]. Available from: http://www.clinicaltrials.gov
- Muenzer J, Prada CE, Burton B, et al. CHAMPIONS: A phase 1/2 clinical trial with dose escalation of SB-913 ZFN-mediated in vivo human genome editing for treatment of MPS II (Hunter syndrome). Mol Genet Metab. 2019;126(2):S104. doi: https://doi.org/10.1016/j.ymgme.2018.12.263
- ClinicalTrials.gov [Internet]. Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics: A safety and efficacy study evaluating CTX001 in subjects with severe sickle cell disease [ClinicalTrials.gov identifier NCT03745287]. [cited 19.09.2019]. Available from: http:// https://clinicaltrials.gov/ct2/show/NCT03745287
- Psatha N, Reik A, Phelps S, et al. Disruption of the BCL11A Erythroid Enhancer Reactivates Fetal Hemoglobin in Erythroid Cells of Patients with β-Thalassemia Major. Mol Ther Methods Clin Dev. 2018;10:313–326. doi: https://doi.org/10.1016/j.omtm.2018.08.003
- ClinicalTrials.gov [Internet]. Sangamo Therapeutics: Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects with Severe Hemophilia B [ClinicalTrials.gov identifier NCT02695160]. [cited 19.09.2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT02695160
- ClinicalTrials.gov [Internet]. Allergan and Editas Medicine, Inc.: Single Ascending Dose Study in Participants with LCA10 [ClinicalTrials.gov identifier NCT03872479]. [cited 19.09.2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT03872479
- Charpentier E, Doudna JA. Biotechnology: Rewriting a genome. Nature. 2013;495(7439):50–51. doi: https://doi.org/10.1038/495050a
- Miyaoka Y, Berman JR, Cooper SB, et al. Systematic quantification of HDR and NHEJ reveals effects of locus, nuclease, and cell type on genome-editing. Sci Rep. 2016;6:23549. doi: https://doi.org/10.1038/srep23549
- Fogarty NME, McCarthy A, Snijders KE, et al. Genome editing reveals a role for OCT4 in human embryogenesis. Nature. 2017;550(7674):67–73. doi: https://doi.org/10.1038/nature24033
- Ma H, Marti-Gutierrez N, Park SW, et al. Correction of a pathogenic gene mutation in human embryos. Nature. 2017;548(7668):413–419. doi: https://doi.org/10.1038/nature23305
- Rm.coe.int [Internet]. Statement on genome editing technologies // Committee on bioethics of the Council of Europe (DH-BIO). [cited 19.09.2019]. Available from: https://rm.coe.int/CoERMPublicCommonSearchServices/DisplayDCTMContent?documentId=090000168049034a
- Nationalacademies.org [Internet]. International summit on Human gene editing // The National academies of sciences, engineering and medicine. [cited 19.09.2019]. Available from: http://www.nationalacademies.org/cs/groups/genesite/documents/webpage/gene_170582.pdf
- Nationalacademies.org [Internet]. On Human Genome Editing II. Statement by the Organizing Committee of the Second International Summit on Human Genome Editing. [cited 19.09.2019]. Available from: http://www8.nationalacademies.org/onpinews/newsitem.aspx?RecordID=11282018b
- Lander ES, Baylis F, Zhang F, et al. Adopt a moratorium on heritable genome editing. Nature. 2019;567(7747):165–168. doi: https://doi.org/10.1038/d41586-019-00726-5
- Morrison M, de Saille S. CRISPR in context: towards a socially responsible debate on embryo editing. Palgrave Commun. 2019;5;110. doi: https://doi.org/10.1057/s41599-019-0319-5
- Who.int [Internet]. WHO launches global registry on human genome editing. [cited 19.09.2019]. Available from: https://www.who.int/news-room/detail/29-08-2019-who-launches-global-registry-on-human- genome-editing
- Tooley M. Abortion and Infanticide. N.Y.: Oxford University Press; 1984. 448 p.
- Тищенко П.Д., Юдин Б.Г. Социогуманитарное сопровождение инновационных проектов в биомедицине // Знание. Понимание. Умение. — 2016. — № 2. — С. 73–86. [Tishchenko PD, Yudin BG. Social and humanitarian support of innovative biomedical projects. Znanie. Ponimanie. Umenie. 2016;2:73–86. (In Russ.)] doi: https://doi.org/10.17805/zpu.2016.2.7
- vanderbilt.edu [Internet]. Beyond Therapy: Biotechnology and the Pursuit of Happiness. [cited 26.09.2019]. Available from: http://www.vanderbilt.edu/olli/files/Beyond-Therapy-Kass.pdf
- Murray ТН. Enhancement. In: Steinbock B. (ed.). The Oxford Handbook of Bioethics. N.Y.: Oxford University Press; 2007. 768 p.
Supplementary files
